HIV Non Occupational Post-Exposure Prophylaxis (PEP)
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be
for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in
HIV uninfected adults.
Phase:
Phase 4
Details
Lead Sponsor:
Fenway Community Health
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium Tenofovir